ArticleDigestive diseases and sciences2026
Hematologic and Inflammatory Biomarker-Based Prognostic Assessment in Acute Pancreatitis: The Role of CRP, Procalcitonin, and CRP/Albumin Ratio.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsAcute pancreatitis (AP) is an inflammatory disease with high morbidity and mortality, characterized by the activation of pancreatic enzymes within the pancreas, leading to autolysis. The clinical spectrum of AP ranges from edematous pancreatitis to necrotizing pancreatitis and may result in local complications such as pancreatic necrosis, pseudocysts, and peripancreatic fluid collections. In this study, we aimed to evaluate the prognostic value of daily C-reactive protein (CRP), procalcitonin, and CRP/albumin levels in predicting local complications of pancreatitis. MATERIALS AND
methodsThe study included 350 patients with AP, who were hospitalised at Bilkent City Hospital, between 1 January 2020 and 31 December 2023. Demographic data, AP etiologies, and biochemical parameters were recorded. The daily trajectories of CRP, procalcitonin, and albumin levels were monitored over 14 days. All statistical analyses were performed using SPSS version 22.
resultsTo distinguish cases with and without peripancreatic fluid collection, the cutoff values for CRP on the first, second, and third days were determined as ≥ 30, ≥ 33, and ≥ 59 (AUC: 0.6574; 0.8343; 0.8897), respectively. The cutoff values for procalcitonin were ≥ 0.09, ≥ 0.07, and ≥ 0.12 (AUC: 0.6457; 0.7227; 0.7310), while for CRP/albumin, the cutoff values were ≥ 0.2609, ≥ 1.0476, and ≥ 1.7143 (AUC: 0.6586; 0.8314; 0.8856), respectively. For distinguishing acute peripancreatic fluid collection (APFC) from WON-pseudocyst, the cutoff values for CRP on the first, second, and third days were determined as ≥ 79, ≥ 124, and ≥ 131 (AUC: 0.7428; 0.8360; 0.9613), respectively. The cutoff values for procalcitonin were ≥ 0.18, ≥ 0.13, and ≥ 0.10 (AUC: 0.7403; 0.8493; 0.8967), while for the CRP/albumin ratio, the cutoff values were ≥ 2.000, ≥ 3.000, and ≥ 2.9556 (AUC: 0.7530; 0.8368; 0.9634), respectively. For distinguishing pseudocyst from walled-off necrosis (WON), the cutoff values for CRP on the first, second, and third days were determined as ≥ 234, ≥ 91, and ≥ 229 (AUC: 0.5750; 0.6285; 0.7148), respectively. The cutoff values for procalcitonin were ≥ 0.96, ≥ 0.39, and ≥ 0.69(AUC: 0.6083; 0.6813; 0.7319), while for the CRP/albumin ratio, the cutoff values were ≥ 6.50, ≥ 5.3684, and ≥ 7.3571 (AUC: 0.5603; 0.6357; 0.7456), respectively.
conclusionOur study indicated that the daily variations in CRP, procalcitonin, and CRP/albumin ratio were significantly associated with AP complications.
Indexed as
Identifiers
42406297What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.